Search

Innovations in posterior uveitis: In conversation with Dr Colin Chu

A research team has been awarded significant funding by the National Institute for Health and Care Research (NIHR) to develop an innovative drug-device combination that aims to revolutionise how individual immune cells are monitored and treated in patients at Moorfields...

Developments in retinal pigmentation measurement and the hopes of an equitable future

Our AI & Oculomics co-editor, Nima Ghadiri, sat down with Abraham Olvera-Barrios from Moorfields and Anand Rajesh from the University of Washington to discuss their recent international study into retinal pigmentation and its wider clinical, technological and academic applications. Can...

Volunteer abroad: the Khmer Sight Foundation

A team of volunteers describe their experiences of working with the Khmer Sight Foundation in Cambodia. Cambodia has a population of 15 million people, of whom an estimated 300,000 are blind. This figure is increasing by 10,000 each year. Three-quarters...

Establishing an intra-arterial chemotherapy service for children with retinoblastoma in Nigeria for the first time

This is the first in a series of three articles (see Part 2 here) about strengthening eye health services in Nigeria through collaboration with the LINKS and Networks run at the International Centre for Eye Health, London School of Hygiene...

Changing the post cataract surgery review pathway – is patient safety compromised?

Cataract surgery continues to be the most commonly performed elective surgical procedure in the UK, with an annual rate of approximately 4150/100,000 people over the age of 65 accounting for a significant proportion of the surgical workload of most ophthalmologists...

Corporate M&A pace gathers momentum

Intensifying franchise competition, maturing product development pipelines and looming loss of exclusivity spur renewed merger and acquisition (M&A) activity in the ophthalmics sector. Rod McNeil reviews recent deals and related strategic developments. AbbVie to acquire Allergan in $63 billion mega-combination,...

Retinoblastoma – the challenges of a rare cancer and the role of international partnerships

Introduction: the global challenge The global burden of retinoblastoma (Rb) is one in 15,000-18,000 live births, which equates to 8000 new cases worldwide each year. The global disparities in Rb outcome represent a paradigm of health inequality worldwide [1]. In...

Second sight: Ian McKinley

I have always been captivated by a true-life story demonstrating the human spirit of triumph over adversity. For me, one of the most memorable sportsmen overcoming an injury has always been the mountaineer Joe Simpson and his tale of survival...